NCT03433352

Intestinal Microbiota and Treatment of GD

The Effect of Intestinal Microbiota on Treatment Sensitivity and Prognosis of Methimazole for GD

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 90 (estimated)
• Sponsor: First Affiliated Hospital of Harbin Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

Graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. Many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. Investigators systematically performed a comparative analysis of the gut microbiota in GD patients and healthy controls and analyse the relationship between intestinal microbiota and GD drug therapy.

Detailed description

Graves' disease is an organ-specific autoimmune disease in which both genetic predisposition and environmental factors serve as disease triggers. Many studies have indicated that alterations in the gut microbiota are important environmental factors in the development of inflammatory and autoimmune diseases. Investigators systematically performed a comparative analysis of the gut microbiota in GD patients and healthy controls before and found that gut microbiota changed between GD patients and healthy controls.But there are few articles on the relationship between intestinal microbiota and drug treatment of GD, so Investigators explored the relationship between intestinal microflora and methimazole treatment for GD.

Conditions

• Microbiota

Interventions

Type	Name	Description
DRUG	Methimazole Pill	Patients who developed GD received methimazole treatment
DRUG	Propylthiouracil Pill	Patients who developed GD received propylthiouracil treatment

Timeline

• Start date: 2017-12-23
• Primary completion: 2018-12-23
• Completion: 2019-12-20
• First posted: 2018-02-14
• Last updated: 2018-02-14

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study